2025-04-13 20:37:25
Latest Post
IPO-bound Belrise Industries Ltd completes strategic acquisition of H-One India Private Limited
Mitsu Chem Plast Eyes ₹ 1,000 Cr Revenue by 2028
Aurobindo Pharma receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg
NHPC Ltd commissions commercial operation of 107.14 MW of 300 MW Karnisar Solar Power Plant
Nureca Limited's Manufacturing Subsidiary Secures US FDA Registration
Stock Report
Gland Pharma Ltd Q2FY22 consolidated PAT slips QoQ to Rs. 302.08 crore
Posted On : 2021-10-22 17:27:42( TIMEZONE : IST )
Gland Pharma Limited has reported Consolidated financial results for the period ended September 30, 2021.
Financial Results (Q2 FY2022) - QoQ Comparison
The company has reported total income of Rs. 1131.666 crores during the period ended September 30, 2021 as compared to Rs. 1215.738 crores during the period ended June 30, 2021.
The company has posted net profit / (loss) of Rs. 302.081 crores for the period ended September 30, 2021 as against net profit / (loss) of Rs. 350.652 crores for the period ended June 30, 2021.
The company has reported EPS of Rs. 18.37 for the period ended September 30, 2021 as compared to Rs. 21.37 for the period ended June 30, 2021.
| Financials | Q2 FY2022 | Q1 FY2022 | % Change |
| Total Income | ₹ 1131.666 crs | ₹1215.738 crs |  -6.92% |
| Net Profit | ₹302.081 crs | ₹350.652 crs | -13.85% |
| EPS | ₹18.37 | ₹21.37 | -14.04% |
Financial Results (Q2 FY2022) - YoY Comparison
The company has reported total income of Rs. 1131.666 crores during the period ended September 30, 2021 as compared to Rs.851.852 crores during the period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.302.081 crores for the period ended September 30, 2021 as against net profit / (loss) of Rs.218.857 crores for the period ended September 30, 2020.
The company has reported EPS of Rs.18.37 for the period ended September 30, 2021 as compared to Rs.14.12 for the period ended September 30, 2020.
| Financials | Q2 FY2022 | Q2 FY2021 | % Change |
| Total Income | ₹ 1131.666 crs | ₹851.852 crs |  32.85% |
| Net Profit | ₹302.081 crs | ₹218.857 crs | 38.03% |
| EPS | ₹18.37 | ₹14.12 | 30.10% |
Financial Results (Half Year Ended FY2022) - YoY Comparison
The company has reported total income of Rs.2347.404 crores during the 6 Months period ended September 30, 2021 as compared to Rs.1768.141 crores during the 6 Months period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.652.733 crores for the 6 Months period ended September 30, 2021 as against net profit / (loss) of Rs.532.447 crores for the 6 Months period ended September 30, 2020.
The company has reported EPS of Rs.39.78 for the 6 Months period ended September 30, 2021 as compared to Rs.34.36 for the 6 Months period ended September 30, 2020.
| Financials | Half Year Ended FY2022 | Half Year Ended FY2021 | % Change |
| Total Income | ₹2347.404 crs | ₹1768.141 crs | 32.76% |
| Net Profit | ₹652.733 crs | ₹532.447 crs | 22.59% |
| EPS | ₹39.78 | ₹34.36 | 15.77% |
Shares of Gland Pharma Limited was last trading in BSE at Rs. 3693.65 as compared to the previous close of Rs. 3617.90. The total number of shares traded during the day was 8747 in over 2692 trades.
The stock hit an intraday high of Rs. 3720.00 and intraday low of 3584.70. The net turnover during the day was Rs. 32096598.00.
